Detect neck norepinephrine nerve loss
- Trial ID
- NCT05741151
- Official Title
- Evaluation of Peripheral Catecholaminergic System in Neurodegenerative Diseases of the Central Nervous System. A Pilot Study.
- Goal
- Detect neck norepinephrine nerve loss
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study Type
- INTERVENTIONAL
- Enrollment
- 18 participants
- Conditions
- Parkinson Disease
- Interventions
- PET-Neck Parkinsonian patients
Plain-Language Summary
The team wants to find out whether the peripheral catecholaminergic system in the neck, meaning the norepinephrine-producing nerve endings that reflect autonomic involvement, is damaged in people with Parkinson's, which could help with diagnosis and understanding how the disease spreads. Participants get a PET scan with a tracer that lights up catecholamine nerve terminals in the neck so clinicians can see loss or preservation of those fibers; the scan is diagnostic only and does not change medications or interact with levodopa. Enrollment is for adults 30 to 80 who meet Movement Disorder Society criteria for Parkinson's, excluding people with clear atypical features such as cerebellar signs, vertical gaze palsy, drug-induced parkinsonism, no response to high-dose levodopa, normal presynaptic dopamine imaging, parkinsonism limited to the legs for more than three years, or another diagnosis that better explains the symptoms.
Locations
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying PET-Neck Parkinsonian patients. The team wants to find out whether the peripheral catecholaminergic system in the neck, meaning the norepinephrine-producing nerve endings that reflect autonomic involvement, is damaged in people with Parkinson's, which could help with diagnosis and understanding how the disease spreads. Participants get a PET scan with a tracer that lights up catecholamine nerve terminals in the neck so clinicians can see loss or preservation of those fibers; the scan is diagnostic only and does not change medications or interact with levodopa. Enrollment is for adults 30 to 80 who meet Movement Disorder Society criteria for Parkinson's, excluding people with clear atypical features such as cerebellar signs, vertical gaze palsy, drug-induced parkinsonism, no response to high-dose levodopa, normal presynaptic dopamine imaging, parkinsonism limited to the legs for more than three years, or another diagnosis that better explains the symptoms.
- Who can participate?
- Participants must be between 30 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.